The Oral Mucositis drugs in development market research report provides comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Oral Mucositis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued products.

GlobalData tracks 15 drugs in development for Oral Mucositis by 13 companies/universities/institutes. The top development phase for Oral Mucositis is preclinical with seven drugs in that stage. The Oral Mucositis pipeline has 13 drugs in development by companies and two by universities/ institutes. Some of the companies in the Oral Mucositis pipeline products market are: GlycoMira Therapeutics, Destiny Pharma and Clevexel Pharma.

The key targets in the Oral Mucositis pipeline products market include P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP), NACHT LRR And PYD Domains Containing Protein 3 (Caterpiller Protein 1.1 or Cold Autoinflammatory Syndrome 1 Protein or Cryopyrin or Nucleotide Binding Oligomerization Domain Leucine Rich Repeat And Pyrin Domain Containing 3 or NLRP3), and Prostaglandin E2 Receptor EP1 Subtype (Prostanoid EP1 Receptor or PTGER1).

The key mechanisms of action in the Oral Mucositis pipeline product include P Selectin (CD62 Antigen Like Family Member P or Granule Membrane Protein 140 or Leukocyte Endothelial Cell Adhesion Molecule 3 or LECAM3 or Platelet Activation Dependent Granule External Membrane Protein or CD62P or SELP) Inhibitor with two drugs in Preclinical. The Oral Mucositis pipeline products include eight routes of administration with the top ROA being Oral and two key molecule types in the Oral Mucositis pipeline products market including Small Molecule, and Recombinant Protein.

Oral Mucositis overview

Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy, and radiation. Symptoms include change in mucosa color, hyposalivation, a change in the integrity of the mucosa, and the presence of edema on the lips and/or the tongue. Treatment includes oral decontamination (mouth care) and oral debridement.

For a complete picture of Oral Mucositis’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.